Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory indolent non-Hodgkin lymphoma from the ongoing phase 1 CaDAnCe-101 study

View Full Paper
Ask AI
Bookmark
Share

Authors

DYDok Hyun YoonEMEric MouPZPier Luigi Zinzani

Discussion

Loading...

Member takes

Overview

Phase 1 trial reveals BGB-16673 shows tolerability and 41.2% response rate in follicular lymphoma, suggesting new potential for treatment.

Key Points

  • Assess efficacy and safety of BGB-16673 in relapsed/refractory indolent non-Hodgkin lymphoma patients.
  • Phase 1 study of BGB-16673 monotherapy in patients with FL and MZL.
  • Patients had ≥2 prior therapies, including anti-CD20 antibodies or BTK inhibitors.
  • Safety assessed according to NCI-CTCAE v5.0; ORR evaluated per 2014 Lugano criteria.
  • Overall response rate was 41.2% for follicular lymphoma and 54.8% for marginal zone lymphoma.
  • Major adverse events included gastrointestinal hemorrhage and febrile neutropenia related to treatment.
  • 25% of patients with follicular lymphoma experienced grade ≥3 adverse events.

Cite This Study

Yoon et al. (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d9b3https://doi.org/10.1182/blood-2025-3584
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Richter transformation: Results from the ongoing phase 1 CaDAnCe-101 study2025 · 1 citations
  2. 2CaDAnCe-104, an ongoing, open-label, phase 1b/2 master protocol study of Bruton tyrosine kinase degrader BGB-16673 in combination with other agents in patients with relapsed/refractory B-cell malignancies2025 · 3 citations
  3. 3Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Waldenström macroglobulinemia from the ongoing phase 1 CaDAnCe-101 study2025 · 4 citations
  4. 4CaDAnCe-304, a phase 3, open-label, randomized study to evaluate the safety and efficacy of Bruton tyrosine kinase degrader BGB-16673 compared with pirtobrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma2025 · 1 citations
  5. 5CaDAnCe-302, a phase 3, open-label, randomized study of BGB-16673 compared with idelalisib + rituximab (R), bendamustine + R, or venetoclax + R re-treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma previously exposed to both a BTK and BCL2 inhibitor2025